SOPHiA GENETICS SA (NASDAQ: SOPH) sees dramatic decline in short interest

Sophia Genetics St.Nasdaq: SOPHGet the rating) was the target of a significant drop in short interest rates in August. As of August 15, there was a short interest total of 126,300 shares, down 23.8% from the July 31 total of 165,800 shares. Currently, 0.3% of the shares are being short sold. Based on an average trading volume of 92,400 shares, the ratio of days to coverage is currently 1.4 days.

Sophia genes price performance

Sufi It traded down $0.28 during Friday’s trading, to $3.69. The company’s stock trading volume was 75,896 shares, compared to an average trading volume of 86,899 shares. The company’s 50-day moving average is $3.70 and the 200-day moving average is $6.05. The stock has a market capitalization of $233.72 million and a PE ratio of -2.51. SOPHiA GENETICS has a twelve-month low of $2.16 and a twelve-month high of $19.80.

Sophia genesNasdaq: SOPHGet the rating) last released its quarterly earnings results on Tuesday, August 9th. The company reported earnings ($0.39) per share for the quarter, in line with consensus estimates of $0.39. The company generated revenue of $11.67 million for the quarter, compared to the consensus estimate of $11.77 million. SOPHiA GENETICS had a negative return on equity of 35.51% and a negative net margin of 211.72%. Stock analysts expect SOPHiA GENETICS to report earnings of 1.47 per share for the current year.

Wall Street Analyst Weighs In


ad trade

The safest choice in trades!

If you are new to the world of trading, you may have heard something wrong about options – namely that they are risky, unpredictable or difficult. It couldn’t be more wrong! With the Hughes Optioneering Strategy, you will soon know that the safest option for new accounts is the options themselves!

Separately, Morgan Stanley cut its price target on SOPHiA GENETICS from $14.00 to $13.00 and placed an “overweight” rating on the stock in a research note on Wednesday, August 10th.

Institutional Trade in SOPHiA GENETICS

A number of institutional investors and hedge funds have recently made changes to their positions in SOPH. Zurcher Cantonalbank Zurich Cantonalbank bought a new stake in SOPHiA GENETICS during the second quarter valued at $31,000. Renaissance Technologies LLC bought a new stake in SOPHiA GENETICS during the second quarter valued at $63,000. Banque Cantonale Vaudoise consolidated its position in SOPHiA GENETICS by 17.8% during the second quarter. Banque Cantonale Vaudoise now owns 19,900 shares of the company’s stock, valued at $73,000 after purchasing an additional 3,000 shares during the period. Privium Fund Management BV bought a new stake in SOPHiA GENETICS during the second quarter valued at $102,000. Finally, UBS Group AG consolidated its position in SOPHiA GENETICS by 153.4% ​​during the second quarter. UBS Group AG now owns 45,758 shares of the company’s stock valued at $165,000 after purchasing an additional 27,700 shares during the period. 27.64% of the shares are currently owned by institutional investors and hedge funds.

About Sophia Hereditary

(Get the rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers the SOPHiA DDM platform, a cloud-based SaaS platform for analyzing data and generating insights from multimedia datasets and diagnostic methods. The SOPHiA DDM platform and related solutions, products and services are used by hospitals, laboratories and biopharmaceuticals around the world.

in-depth reading

This instant news alert was created by narrative science technology and MarketBeat financial data to provide readers with the fastest and most accurate reporting. This story was reviewed by the Editorial Team at MarketBeat prior to publication. Please send any questions or comments about this story to

Before you consider SOPHiA GENETICS, you’ll want to hear this.

MarketBeat tracks the top-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market hunts… SOPHiA GENETICS wasn’t on the list.

While SOPHiA GENETICS currently has a “buy” rating among analysts, top-rated analysts believe these five stocks are a better buy.

View the five stocks here

Leave a Reply

Your email address will not be published.